NCT04047641
- Conditions
- Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, Hematologic Diseases, +18 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Recurrent High Risk Myelodysplastic Syndrome
Explore clinical trials studying Recurrent High Risk Myelodysplastic Syndrome. Study availability and eligibility vary by location and protocol.
6 public trials
3 recruiting studies
Recurrent High Risk Myelodysplastic Syndrome trial results
NCT03896269
- Conditions
- Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Bone Marrow Diseases, +17 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Recruiting
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
NCT03383575
- Conditions
- Acute Myeloid Leukemia, Anemia, Anemia, Refractory, +22 more
- Locations
-
- Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
- Cleveland Clinic Foundation Cleveland, Ohio, United States
- M D Anderson Cancer Center Houston, Texas, United States
NCT02649764
- Conditions
- Bone Marrow Diseases, Chronic Disease, Chronic Myelomonocytic Leukemia, +16 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Completed
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
NCT02921061
- Conditions
- Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +17 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Active, Not Recruiting
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
NCT02861417
- Conditions
- Blood Protein Disorders, Bone Marrow Diseases, Cardiovascular Diseases, +46 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States